ENGOT-OV16/NOVA

2:26
Trial design of ENGOT-OV16/NOVA Phase III trial of niraparib in platinum-sensitive ovarian cancer
Mansoor Mirza
3:09
The promising potential of PARP inhibitors in ovarian cancer
Jonathan Ledermann
3:10
Overview of ENGOT-OV16/NOVA of niraparib in ovarian cancer and why the results were not surprising
Ursula Matulonis
1:14
Next steps for niraparib for ovarian cancer following on from the ENGOT-OV16/NOVA trial
Sven Mahner
1:13
Comparison of trials of niraparib, olaparib and rucaparib in ovarian cancer
Mansoor Mirza
1:50
Niraparib as maintenance for platinum-sensitive ovarian cancer – results from ENGOT-OV16/NOVA trial
Sven Mahner
2:38
NOVA Phase III trial of niraparib in platinum-sensitive ovarian cancer patients
Nicoletta Colombo
VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJO needs the contact information you provide to inform you about our latest oncology news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJOncology is intended for healthcare professionals